Search

Your search keyword '"P. Cassier"' showing total 168 results

Search Constraints

Start Over You searched for: Author "P. Cassier" Remove constraint Author: "P. Cassier" Search Limiters Full Text Remove constraint Search Limiters: Full Text
168 results on '"P. Cassier"'

Search Results

1. Long time behaviour of the solution of Maxwell's equations in dissipative generalized Lorentz materials (II) A modal approach

2. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.

3. Epidemiologic characteristics associated with ST23 clones compared to ST1 and ST47 clones of Legionnaires disease cases in France

5. Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

6. Long time behaviour of the solution of Maxwell's equations in dissipative generalized Lorentz materials (I) A frequency dependent Lyapunov function approach

7. Active exterior cloaking for the 2D Helmholtz equation with complex wavenumbers and application to thermal cloaking

9. Spectral theory for Maxwell's equations at the interface of a metamaterial. Part II: Limiting absorption, limiting amplitude principles and interface resonance

10. High contrast elliptic operators in honeycomb structures

11. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer

13. Active Thermal Cloaking and Mimicking

14. Harnack parts for some truncated shifts

15. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

16. Electromagnetic waves in photonic crystals: laws of dispersion, causality and analytical properties

17. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

18. Imaging small polarizable scatterers with polarization data

19. Slowdown of the surface diffusion during early stages of bacterial colonization

20. Search for rings and satellites around the exoplanet CoRoT-9b using Spitzer photometry

21. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

22. Mathematical models for dispersive electromagnetic waves: an overview

23. Imaging polarizable dipoles

24. HARNACK parts of $\rho$-Contractions

25. Bounds on Herglotz functions and fundamental limits of broadband passive quasi-static cloaking

26. Spectral theory for Maxwell's equations at the interface of a metamaterial. Part I: Generalized Fourier transform

27. SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4

29. A rigorous approach to the field recursion method for two-component composites with isotropic phases

30. Analyticity of the Dirichlet-to-Neumann map for the time-harmonic Maxwell's equations

31. Extended spectrum and extended eigenspaces of quasi-normal operators

33. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

35. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

36. Resultats de cyclicite pour des operateurs de Toeplitz anti-analytiques

38. Constrained von Neumann inequalities

39. Semigroups in finite von Neumann algebras

40. The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death

42. Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

43. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

47. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

49. 76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

50. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

Catalog

Books, media, physical & digital resources